20:23 , Jun 4, 2019 |  BC Extra  |  Clinical News

June 4 ASCO Quick Takes: Sarcoma data for Aadi's nab-sirolimus; plus c-MET inhibitor data for NSCLC

Aadi's ABI-009 leads to 42% ORR in rare sarcoma  Aadi Bioscience Inc. (Pacific Palisades, Calif.) reported at ASCO Monday that nab-sirolimus (ABI-009) led to a confirmed investigator-assessed objective response rate of 42%, all partial responses,...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
01:12 , Jun 1, 2019 |  BioCentury  |  Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines. In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating...
23:52 , May 30, 2019 |  BC Innovations  |  Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
20:53 , May 17, 2019 |  BC Extra  |  Clinical News

AbbVie's antibody-drug conjugate misses mark in Phase III GBM trial

In a second setback for glioblastoma multiforme patients this month, AbbVie said its depatuxizumab mafodotin missed the primary endpoint of improving overall survival in the Phase III INTELLANCE-1 for newly diagnosed EGFR-amplified GBM. AbbVie Inc....
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
15:54 , Apr 17, 2019 |  BC Extra  |  Financial News

Turning Point gains after pricing upsized $166.5M IPO

Turning Point shares jumped $10.90 (61%) to $28.90 in their first day of trading Wednesday after the company raised $166.5 million in an upsized IPO priced late Tuesday. Turning Point Therapeutics Inc. (NASDAQ:TPTX) sold 9.3...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Merrimack's bispecific mAb against c-MET and EpCAM for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; gastric cancer; lung cancer Cell culture and mouse studies identified a bispecific mAb against c-MET and EpCAM that could help treat colorectal, lung and gastric cancers. In human colorectal...
20:27 , Mar 19, 2019 |  BC Extra  |  Preclinical News

Merrimack develops bispecific against c-MET oncogene

Merrimack has overcome hurdles to antibody targeting of c-MET with a bispecific that increases avidity by anchoring to a tumor surface protein. Marketed small molecules inhibiting c-MET, which drives tumor formation, metastasis and resistance to...